NCT03025035: Pembrolizumab in Advanced BRCA-mutated Breast Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Patient must have a BRCA (inherited mutation; Restrictions on the number of lines of previous treatment- see trial for details
Exclusions: Patients with known active untreated central nervous system (CNS) metastases and/or leptomeningeal disease- see trial for details; Patients with non-measurable bone disease as the only site(s) of disease; Patients who have received prior anti-PD-1, -PD-L1/2, -CD137, or -CTLA-4 therapy

Comments are closed.

Up ↑